Critical Medicines Sandoz Inaugurates New Antibiotic Production Plant, Biosimilar Development Center

Source: Press release Sandoz International 1 min Reading Time

Related Vendors

Sandoz has launched a new antibiotic production plant in Austria along with a biosimilar development center in Germany. The units are in line with the firm’s aim to strengthen sustainable development and supply of critical medicines in Europe and other regions of the world.

Sandoz has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.(Source:  Rido - stock.adobe.com)
Sandoz has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.
(Source: Rido - stock.adobe.com)

Basel/Switzerland – Sandoz has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.

The inauguration of a new facility for production of penicillin at Kundl, Austria, and a new biosimilar development center in Holzkirchen, Germany, reaffirm the dual Sandoz commitment to ensuring sustainable access to quality antibiotics and spearheading development of biosimilars.

Sandoz has the only major remaining vertically-integrated production network for penicillins in Europe; penicillins are the leading category of antibiotics worldwide. The 150 million-euro Kundl investment, which includes a contribution of 50 million euros from the Austrian federal government, represents a significant upgrade of penicillin API (active pharmaceutical ingredient) manufacturing.

Richard Saynor, CEO Sandoz said: "These investments strengthen our industrial presence in Europe, reinforce our commitment to environmental responsibility, and reaffirm our determination to be the world's leading and most valued generics and biosimilars company. Antibiotics are the backbone of modern medicine and the Kundl plant is a testament to the resilience of European manufacturing. The new development center in Holzkirchen will become a global hub for biosimilar expertise."

The 25 million-euro Holzkirchen investment will pave the way for the German site to become the leading Sandoz analytical characterization center for biosimilars.

The Austrian federal and Bavarian state governments have been highly supportive of these projects, recognizing their importance for ensuring availability of medicines and advancing medical research in Europe.

(ID:49788246)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent